Amwill Health Care Ltd
Incorporated in 2009, Amwill Health Care is in the wholesale trading of pharmaceutical products[1]
- Market Cap ₹ 104 Cr.
- Current Price ₹ 52.0
- High / Low ₹ 105 / 50.0
- Stock P/E 9.69
- Book Value ₹ 34.6
- Dividend Yield 0.00 %
- ROCE 27.6 %
- ROE 24.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 46.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has high debtors of 163 days.
- Working capital days have increased from 79.6 days to 166 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 17 | 26 | 28 | 42 | 37 | |
| 18 | 22 | 24 | 25 | 26 | |
| Operating Profit | -1 | 4 | 4 | 17 | 12 |
| OPM % | -6% | 14% | 15% | 40% | 31% |
| 0 | -0 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -1 | 3 | 4 | 17 | 12 |
| Tax % | -3% | 23% | 25% | 25% | 10% |
| -1 | 3 | 3 | 12 | 11 | |
| EPS in Rs | -333.33 | 856.67 | 1,036.67 | 2,500.00 | 5.36 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | -10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 60% |
| TTM: | -14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 46% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.05 | 20 |
| Reserves | -1 | 1 | 5 | 17 | 49 |
| 0 | 0 | 0 | 0 | 0 | |
| 9 | 5 | 8 | 2 | 2 | |
| Total Liabilities | 8 | 7 | 12 | 19 | 71 |
| 1 | 0 | 1 | 1 | 1 | |
| CWIP | 0 | 0 | 0 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 7 | 6 | 12 | 18 | 70 | |
| Total Assets | 8 | 7 | 12 | 19 | 71 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 0 | 3 | 5 | -3 | 6 | |
| -1 | -0 | -1 | -1 | -46 | |
| 0 | 0 | -0 | -0 | 41 | |
| Net Cash Flow | -1 | 3 | 3 | -4 | 1 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 93 | 12 | 16 | 114 | 163 |
| Inventory Days | 66 | ||||
| Days Payable | 39 | ||||
| Cash Conversion Cycle | 93 | 12 | 16 | 141 | 163 |
| Working Capital Days | -45 | -25 | -38 | 111 | 166 |
| ROCE % | 1,069% | 133% | 153% | 28% |
Documents
Announcements
-
Board Meeting Intimation for For Convening The Board Meeting On Thursday, October 30, 2025 For Consideration And Approval Of Unaudited Financial Results For H1 FY26 Has Been Rescheduled And Will Now Be Held On Tuesday, November 04, 2025.
11h - Board meeting rescheduled to Nov 4, 2025 to approve H1 results (Sept 30); trading window closed until 48 hours post-results.
-
Board Meeting Intimation for Convening The Board Meeting On Thursday, October 30, 2025 For Consideration And Approval Of Unaudited Financial Results For H1 FY26.
24 Oct - Board meeting 30-Oct-2025 to approve H1 FY2025-26 unaudited results; trading window closed Oct 1, opens 48h after.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Oct - Compliance Certificate Under Regulation 74(5) of the SEBI ( Depositories and Participants) Regulations, 2018, for 2nd Quarter ended September 30, 2025.
- Closure of Trading Window 26 Sep
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
14 Aug - E-voting results of 8th AGM: all 6 resolutions including financials and director appointments passed.
Business Overview:[1][2]
a) AHL focuses on Dermatology, Trichology, and Cosmetology.
b) It creates advanced skincare solutions using dermatological actives, natural ingredients, and specialized techniques.
c) Operates as a dermal-cosmetic developer, collaborating with contract manufacturers, distributors, and third-party developers.
d) Follows an asset-light model, outsourcing testing, manufacturing, and distribution.